Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
Healthcare
$27.74 +2.60%
+$0.88 today
- Market cap
- $4.83B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
52W Low $6.92High $43.73
Volume 1.68M
Average 2.15M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$264.44M
FY 2025 · Annual
Investing Cash Flow
-$399.53M
FY 2025 · Annual
Financing Cash Flow
$878.23M
FY 2025 · Annual
+309.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.69M | 18.37M | 30.62M | 39.74M | 46.08M |
| Change in Working Capital | 2.02M | 751K | 11.44M | 11.6M | 8.01M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.75M | 2.36M | 4.81M | 1.36M | (2.51M) |
| Other Working Capital | (731K) | (1.61M) | 6.63M | 10.24M | 10.52M |
| Other Non-Cash Items | (343K) | (3.39M) | (6.87M) | (7.62M) | 5.82M |
| Operating Cash Flow | (58.76M) | (118.64M) | (153.62M) | (207.79M) | (264.44M) |
| Capital Expenditures | (1.72M) | (6.86M) | (2.8M) | (573K) | (1.55M) |
| Acquisitions (Net) | 0 | 117.86K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (177.86M) | (348.8M) | (255.6M) | (687.17M) |
| Sales of Investments | 0 | 60M | 253.78M | 294.45M | 289.2M |
| Other Investing Activities | 0 | (117.86K) | 0 | 0 | 0 |
| Investing Cash Flow | (1.72M) | (124.72M) | (97.82M) | 38.28M | (399.53M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 215.13M |
| Common Stock Issued | 38.01M | 161.95M | 161.82M | 213.34M | 712M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30K) | 1.61M | 0 | 1.12M | (48.9M) |
| Financing Cash Flow | 37.98M | 163.56M | 163.54M | 214.45M | 878.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.51M) | (79.8M) | (87.91M) | 44.94M | 214.26M |
| Free Cash Flow | (60.48M) | (125.5M) | (156.42M) | (208.36M) | (266M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$328.9M
+ D&A$4.6M
+ Stock-Based Comp$46.1M
+ Deferred Tax$0
+ Working Capital$8.0M
+ Other Non-Cash$5.8M
= Operating Cash Flow-$264.4M
- Capex-$1.6M
= Free Cash Flow-$266.0M
Analysis
FY2025 free cash flow is -$266.0M. FCF conversion is 80.9% of net income. Operating cash flow was -$264.4M, with capex of -$1.6M. The largest bridge item is Stock-Based Comp at $46.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 8-K | Current report | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 31, 2026 |
Does COGT generate free cash flow?
Cogent Biosciences, Inc. (COGT) generated -$266.00M of free cash flow in fiscal 2025.
How much operating cash flow does COGT produce?
Operating cash flow was -$264.44M, before capital expenditures of $1.55M.
Continue the stock analysis
Jump to another research area for this company.